118 related articles for article (PubMed ID: 8137961)
41. The use of flutamide in the management of hirsutism.
Marugo M; Bernasconi D; Meozzi M; Del Monte P; Zino V; Primarolo P; Badaracco B
J Endocrinol Invest; 1994 Mar; 17(3):195-9. PubMed ID: 8051342
[TBL] [Abstract][Full Text] [Related]
42. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
Mastorakos G; Koliopoulos C; Creatsas G
Fertil Steril; 2002 May; 77(5):919-27. PubMed ID: 12009344
[TBL] [Abstract][Full Text] [Related]
43. Management of hirsutism.
Falsetti L; Gambera A; Platto C; Legrenzi L
Am J Clin Dermatol; 2000; 1(2):89-99. PubMed ID: 11702316
[TBL] [Abstract][Full Text] [Related]
44. Effect of gonadotropin-releasing hormone agonist and medroxyprogesterone acetate on calcium metabolism: a prospective, randomized, double-blind, placebo-controlled, crossover trial.
Carr BR; Breslau NA; Peng N; Adams-Huet B; Bradshaw KD; Steinkampf MP
Fertil Steril; 2003 Nov; 80(5):1216-23. PubMed ID: 14607578
[TBL] [Abstract][Full Text] [Related]
45. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.
Anttila L; Koskinen P; Kaihola HL; Erkkola R; Irjala K; Ruutiainen K
Fertil Steril; 1992 Oct; 58(4):697-702. PubMed ID: 1426312
[TBL] [Abstract][Full Text] [Related]
46. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain.
Schlaff WD; Carson SA; Luciano A; Ross D; Bergqvist A
Fertil Steril; 2006 Feb; 85(2):314-25. PubMed ID: 16595206
[TBL] [Abstract][Full Text] [Related]
47. Etiological review of hirsutism in 250 patients.
Morán C; Tapia MC; Hernández E; Vázquez G; García-Hernández E; Bermúdez JA
Arch Med Res; 1994; 25(3):311-4. PubMed ID: 7803980
[TBL] [Abstract][Full Text] [Related]
48. Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial.
Grant P
Phytother Res; 2010 Feb; 24(2):186-8. PubMed ID: 19585478
[TBL] [Abstract][Full Text] [Related]
49. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
Erenus M; Yücelten D; Gürbüz O; Durmuşoğlu F; Pekin S
Fertil Steril; 1996 Aug; 66(2):216-9. PubMed ID: 8690104
[TBL] [Abstract][Full Text] [Related]
50. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri.
Scialli AR; Jestila KJ
Fertil Steril; 1995 Aug; 64(2):313-20. PubMed ID: 7615109
[TBL] [Abstract][Full Text] [Related]
51. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism.
Lakryc EM; Motta EL; Soares JM; Haidar MA; de Lima GR; Baracat EC
Gynecol Endocrinol; 2003 Feb; 17(1):57-63. PubMed ID: 12724020
[TBL] [Abstract][Full Text] [Related]
52. Hirsutism--a low dose spironolactone therapy.
Vĕtr M
Acta Univ Palacki Olomuc Fac Med; 1989; 122():239-45. PubMed ID: 2530821
[TBL] [Abstract][Full Text] [Related]
53. Finasteride in the treatment of hirsutism: new therapeutic perspectives.
Tolino A; Petrone A; Sarnacchiaro F; Cirillo D; Ronsini S; Lombardi G; Nappi C
Fertil Steril; 1996 Jul; 66(1):61-5. PubMed ID: 8752612
[TBL] [Abstract][Full Text] [Related]
54. Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass.
Lupoli G; Di Carlo C; Nuzzo V; Vitale G; Russo D; Palomba S; Nappi C
J Endocrinol Invest; 1997 Sep; 20(8):493-6. PubMed ID: 9364254
[TBL] [Abstract][Full Text] [Related]
55. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism.
Müderris II; Bayram F; Güven M
Fertil Steril; 2000 May; 73(5):984-7. PubMed ID: 10785225
[TBL] [Abstract][Full Text] [Related]
56. Management of hirsutism.
Alsantali A; Shapiro J
Skin Therapy Lett; 2009 Sep; 14(7):1-3. PubMed ID: 20039595
[TBL] [Abstract][Full Text] [Related]
57. Investigations in the assessment and management of patients with hirsutism.
Barth JH
Curr Opin Obstet Gynecol; 1997 Jun; 9(3):187-92. PubMed ID: 9263703
[TBL] [Abstract][Full Text] [Related]
58. Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
Beigi A; Sobhi A; Zarrinkoub F
Int J Gynaecol Obstet; 2004 Oct; 87(1):29-33. PubMed ID: 15464773
[TBL] [Abstract][Full Text] [Related]
59. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
60. Dual suppression with oral contraceptive pills in GnRH antagonist cycles for patients with polycystic ovary syndrome undergoing intracytoplasmic sperm injection.
Ozmen B; Sükür YE; Seval MM; Ateş C; Atabekoğlu CS; Sönmezer M; Berker B
Eur J Obstet Gynecol Reprod Biol; 2014 Dec; 183():137-40. PubMed ID: 25461367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
